Post by BridgeBio

We are excited to share our recent publication in American Heart Association's Circulation: Heart Failure about acoramidis’ effects on kidney function.     This manuscript summarizes a series of post-hoc analyses of data from the acoramidis clinical development program in patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, and heart failure. Acoramidis, a near-complete TTR stabilizer, is FDA approved for the treatment of ATTR-CM. These analyses describe observed changes in kidney function following the initiation of acoramidis therapy.     Key observations: Within one month after starting acoramidis, participants experienced a reduction in urinary albumin to creatinine ratio (UACR; a marker of kidney damage) and a hemodynamically mediated, reversible estimated glomerular filtration rate (eGFR, a measure of overall kidney function) dip, that was independently associated with a reduction in the risk of adverse cardiovascular outcomes over the following 12 months of the Phase 3 ATTRibute-CM trial. This observation is consistent with the observation of a numerical difference in cumulative cardiovascular hospitalizations (within one month; see https://lnkd.in/gZDFNe3g ) and the separation (at Month 3; see https://lnkd.in/gnrvbfhu) of time-to-event curves of cardiovascular outcomes previously published; there were no kidney-related adverse events observed in these post-hoc analyses. Over the course of the ATTRibute-CM trial, participants on acoramidis also experienced a reduction in the rate of decline in kidney function (as measured by eGFR slope) compared to placebo and a sustained UACR reduction. The magnitude of the acute eGFR dip in participants treated with acoramidis was positively associated with a reduction in early cardiovascular outcomes; the opposite was observed with placebo.   These exploratory analyses provide additional information on kidney function measures observed among patients with ATTR-CM treated with acoramidis. We are pursuing continued research to better understand the pharmacological and physiological mechanisms that may explain these observations.    To learn more, click on this link to the publication: https://bit.ly/3SsHvs6